Why the study?
In patients with cardiovascular diseases, the protective mechanism of prostacyclin against platelet activation and thrombosis fails for unclear reasons.
Does atherogenic lipid stress (oxLDL) induce platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin via PDE3A activation?
Does atherogenic lipid stress (oxLDL) induce platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin via PDE3A activation?
Atherogenic lipid stress induces platelet hyperactivity by impairing prostacyclin sensitivity via a CD36-PDE3A pathway, providing a mechanistic link between dyslipidemia and thrombosis.
No takes yet. Share an insight, caveat, or question.
Preclinical data link dyslipidemia to platelet hyperactivity via CD36-PDE3A; leaves open translation to human thrombosis risk or therapy.
Berger et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: